

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma introduces a novel class of drug, Fexuclue[®](Fexuprazan) in India for treatment of Erosive Esophagitis

- Fexuprazan has fast onset of action and stable suppression of gastric acid. It can be taken regardless of food intake.
- Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers (P-CABs), implying longer duration of acid suppression which helps to achieve optimal nocturnal symptom control

Mumbai, India, April 07, 2025: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has launched Fexuprazan tablets 40 mg in India under the brand name "FEXUCLUE[®]". FEXUCLUE[®], a novel potassium-competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.

Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE[®](Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.

Kirti Ganorkar, CEO – India Business, Sun Pharma, said, "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE[®] is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life."

Fexuprazan was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population. The primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically. The study met its primary endpoint. Over 95% of the patients achieved Erosive Esophagitis healing by 8 weeks. Fexuprazan was found to be well tolerated in Indian patients.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



About Erosive Esophagitis

Erosive esophagitis is a condition characterized by inflammation and damage to the lining of the esophagus. Erosion or breaks in lining of esophagus due to chronic irritation are typically observed in erosive esophagitis. Most common cause for erosive esophagitis is the chronic irritation due to reflux of stomach content into esophagus known as gastroesophageal reflux. Erosive esophagitis is considered as a type of gastroesophageal reflux disease (GERD) which is commonly associated with symptoms such as heartburn and regurgitation.^{i,ii} The prevalence of GERD in India varies from 7.6% to 30% and erosive esophagitis occurs in almost 9% of GERD patients.ⁱⁱⁱ Despite the availability of medical, endoscopic, and surgical therapy, still many patients of erosive esophagitis fail to achieve healing of erosions and symptom relief and suffer from impaired quality of life.^{iv}

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on [LinkedIn](#) & [X](#) (Formerly Twitter).

About Daewoong Pharmaceutical

Daewoong Pharmaceutical is one of Korea's leading healthcare companies with outstanding new drug development capabilities. Since launching its first new drug, EasyF Solution in 2001, Daewoong has succeeded in developing various new drugs, including the GERD treatment Fexuprazan in 2022 and the SGLT-2 inhibitor diabetes drug Enavogliflozin in 2023, showcasing its strong R&D capabilities. For further information, please visit www.daewoong.com.

References:

ⁱ Antunes C, Sharma A. Esophagitis. [Updated 2023 Aug 7]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK442012/>

ⁱⁱ Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441938/>

ⁱⁱⁱ Bhatia SJ, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. *Indian J Gastroenterol*. 2019 Oct;38(5):411-440

^{iv} Dickman R, et al. Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. *J Neurogastroenterol Motil*. 2015 Jul 30;21(3):309-19

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contacts: Sun Pharma

Investors

Dr. Abhishek Sharma

Tel +91 22 4324 4324, Xtn 2929
Tel (D) +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh

Tel +91 22 4324 4324, Xtn 5373
Tel (D) +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com